Company Overview

Cryo-Cell International, Inc. (CCEL) is a biotechnology services company specializing in the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and cord tissue. The company operates within the biotechnology, life sciences, and healthcare services industries, with a primary focus on preventative medicine and regenerative medicine support services. Its core customers are expectant parents, hospitals, and healthcare providers seeking private stem cell banking solutions.

Founded in 1989, Cryo-Cell is recognized as one of the first private cord blood banks in the world. Over time, the company expanded from cord blood banking into cord tissue preservation as clinical research increasingly supported the potential therapeutic applications of mesenchymal stem cells. Cryo-Cell’s long operating history, early-mover advantage, and exclusive focus on private (family) banking differentiate it from public or hybrid stem cell banks.

Business Operations

Cryo-Cell generates revenue primarily through upfront processing fees and recurring annual storage fees for stem cell preservation services. Its main operating segments include Cord Blood Banking and Cord Tissue Banking, which together represent the vast majority of company revenues. These services involve proprietary processing methods, controlled-rate freezing, and long-term cryogenic storage using liquid nitrogen vapor systems.

Operations are primarily based in the United States, with processing and storage conducted at company-controlled laboratory facilities. Cryo-Cell also supports international clients through distribution agreements, licensing arrangements, and cooperative relationships with foreign medical institutions. The company operates through wholly owned subsidiaries, including Cryo-Cell, Inc., which manages core laboratory and storage operations. Data inconclusive based on available public sources regarding active joint ventures.

Strategic Position & Investments

Cryo-Cell’s strategy centers on expanding its customer base through increased education around stem cell applications, improving operational efficiency, and supporting clinical research that may broaden the future use cases of stored cells. The company has historically invested in laboratory infrastructure upgrades and regulatory compliance to maintain long-term storage reliability and accreditation.

The company has also participated in limited strategic investments related to cellular therapy research and regenerative medicine initiatives, though it does not operate as a drug developer. Cryo-Cell maintains relationships with academic and clinical research organizations to support the potential future therapeutic validation of cord-derived stem cells. Public disclosures do not indicate material acquisitions in recent years; data inconclusive based on available public sources regarding emerging technology investments beyond core stem cell banking.

Geographic Footprint

Cryo-Cell is headquartered in Oldsmar, Florida, which serves as the center of its administrative, laboratory, and storage operations. The company’s primary market is North America, where the majority of its clients are located and where it maintains regulatory oversight and accreditation.

Internationally, Cryo-Cell has a presence through licensed partners and service agreements in Europe, Latin America, and parts of Asia, allowing it to extend services to non-U.S. customers without maintaining extensive foreign infrastructure. While international revenues represent a smaller portion of total revenue compared to domestic operations, these relationships contribute to brand recognition and long-term growth potential.

Leadership & Governance

Cryo-Cell is led by an executive team with long tenure in biotechnology services and healthcare operations, emphasizing regulatory compliance, operational stability, and conservative capital management. The company’s leadership philosophy prioritizes long-term custodianship of biological assets and financial discipline, reflecting the perpetual nature of stem cell storage obligations.

Key executives include:

• Jerome P. Mazur – Chairman, Chief Executive Officer, and President
• Michael A. Doss – Chief Operating Officer
• James R. Peake – Chief Financial Officer (data inconclusive based on available public sources regarding current tenure)
• Francesca G. Long – Vice President of Client Services

The board of directors provides governance oversight with a focus on compliance, risk management, and shareholder interests, consistent with requirements outlined in SEC filings.